Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis

Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis

Background and AimsIncretin-based therapies, including glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, are essential treatments in diabetes management due to their efficacy in glycemic control and the additional benefits of GLP-1 RAs, which includ...

Full description

Bibliographic Details
Main Authors: Long He, Jinwei Li, Xiong Cheng, Li Luo, Yilan Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Pharmacology
Subjects:
GLP-1 receptor agonists
DPP-4 inhibitors
FAERS
adverse events
biliary disorders
pharmacovigilance
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1509561/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1509561/full

Similar Items